Cargando…

Predicting the Impact of Adverse Events and Treatment Duration on Medical Resource Utilization-Related Costs in Hepatitis C Genotype 1 Treatment-Naïve Patients Receiving Antiviral Therapy

OBJECTIVES: Studies on medical resource utilization (MRU) and related costs are important for evaluating the potential patient management and cost-effectiveness implications of antiviral treatments for hepatitis C virus (HCV) infection. The objectives of this study were (i) to compare the MRU and re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akpo, Essè Ifèbi Hervé, Cerri, Karin, Kleintjens, Joris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381112/ https://www.ncbi.nlm.nih.gov/pubmed/25577042 http://dx.doi.org/10.1007/s40273-014-0249-4

Ejemplares similares

Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients
por: Akpo, Essè Ifèbi Hervé, et al.
Publicado: (2015)

Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom
por: Akpo, Esse Ifebi Herve, et al.
Publicado: (2020)

Burden of Pertussis in Adults Aged 50 Years and Older: A Retrospective Database Study in England
por: Harrington, Lauriane, et al.
Publicado: (2023)

1481. Incidence of Pertussis in Older Adults in England and the United Kingdom: A Large, Retrospective Database Analysis
por: Aris, Emmanuel, et al.
Publicado: (2020)

Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B
por: Sohn, Won, et al.
Publicado: (2017)

Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
por: Akpo, Esse I. H., et al.
Publicado: (2017)

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
por: Kieffer, Tara L., et al.
Publicado: (2012)

A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus
por: Fawsitt, Christopher G., et al.
Publicado: (2019)

Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment
por: Kim, Hong Joo, et al.
Publicado: (2016)

Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus
por: Wang, Ye, et al.
Publicado: (2015)

Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis
por: Suwanthawornkul, Thanthima, et al.
Publicado: (2015)

Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis
por: Schultz, Neil M., et al.
Publicado: (2018)

Implications of a Data-Driven Approach to Treatment with Growth Hormone in Children with Growth Hormone Deficiency and Turner Syndrome
por: Kaspers, Stefan, et al.
Publicado: (2013)

Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients
por: Li, Zhanyi, et al.
Publicado: (2017)

Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients
por: Freeman, Leorah, et al.
Publicado: (2021)

Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials
por: Wong, William W. L., et al.
Publicado: (2019)

Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
por: Lee, Hyun Woong, et al.
Publicado: (2017)

Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients
por: Fouad, Magdy, et al.
Publicado: (2021)

Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1
por: Zhu, Gui-Qi, et al.
Publicado: (2016)

Duration of Untreated Psychosis Is Associated with Temporal and Occipitotemporal Gray Matter Volume Decrease in Treatment Naïve Schizophrenia
por: Guo, Xiaofeng, et al.
Publicado: (2013)

Individualized Treatment of Genotype 1 Naïve Patients: An Italian Multicenter Field Practice Experience
por: Mangia, Alessandra, et al.
Publicado: (2014)

Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B
por: Pacheco, Sidelcina Rugieri, et al.
Publicado: (2017)

Hepatitis C Virus Genotype 5 Variability in Treatment-Naïve Patients in South Africa
por: Maunye, Tshegofatso K., et al.
Publicado: (2023)

Emergence of psychiatric adverse events during antipsychotic treatment in AP-naïve children and adolescents
por: Menard, Marie-Line, et al.
Publicado: (2022)

Skeletal Side Effects of Systemic Isotretinoin Treatment: Do They Depend on Age, Gender, Treatment Duration, Daily Dose and Isotretinoin-Naiveness?
por: Özkoca, Defne, et al.
Publicado: (2023)

Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients
por: Raj, V. Stalin, et al.
Publicado: (2017)

Future Considerations for the Evaluation of Hepatitis C Virus Treatments in Pan-Genotypic Therapy for Noncirrhotic Treatment-Naive Patients
por: Calabrese, Martin J., et al.
Publicado: (2018)

Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China
por: Li, Zhao, et al.
Publicado: (2017)

Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China
por: Li, Zhanyi, et al.
Publicado: (2017)

Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam
por: Due, Ong The, et al.
Publicado: (2020)

Phenotypic and Genotypic Shifts in Hepatitis B Virus in Treatment-Naive Patients, Taiwan, 2008–2012
por: Yeh, Chau-Ting, et al.
Publicado: (2017)

Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab
por: Bharmal, Murtuza, et al.
Publicado: (2020)

Adherence to Chronic Hepatitis B Treatment Guideline Recommendations for Laboratory Monitoring of Patients Who Are Not Receiving Antiviral Treatment
por: Juday, Timothy, et al.
Publicado: (2010)

White Matter Integrity, Duration of Untreated Psychosis, and Antipsychotic Treatment Response in Medication-Naïve First Episode Psychosis Patients
por: Kraguljac, Nina Vanessa, et al.
Publicado: (2020)

Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection
por: Wei, Lai, et al.
Publicado: (2018)

HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1
por: Berenguer, Juan, et al.
Publicado: (2019)

COLD-PCR Method for Early Detection of Antiviral Drug-Resistance Mutations in Treatment-Naive Children with Chronic Hepatitis B
por: Phung, Thuy Thi Bich, et al.
Publicado: (2020)

Diagnostic performance of elastography on liver fibrosis in antiviral treatment-naive chronic hepatitis B patients: a meta-analysis
por: Mingkai, Li, et al.
Publicado: (2022)

Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B
por: Hsu, Po-Ke, et al.
Publicado: (2022)

Optimal duration of antiviral treatment in patients with gastrointestinal cytomegalovirus disease at a low and high risk of relapse
por: Jung, Kyung Hwa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_62od5a9sc8o68aq0rgfs41bi6l